Kairos Pharma, LTD. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Kairos Pharma, LTD. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2023 to Q3 2024.
  • Kairos Pharma, LTD. Retained Earnings (Accumulated Deficit) for the quarter ending September 30, 2024 was -$7.84M.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.